Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfusion therapy: associated risks and alternative approaches.

V T Picard, M H Sayers, B S Spinowitz

    ANNA Journal
    |December 1, 1990
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Incidence of West Nile virus infection in the Dallas-Fort Worth metropolitan area during the 2012 epidemic.

    Epidemiology and infection·2016
    Same author

    Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program.

    The Annals of pharmacotherapy·2001
    Same author

    Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.

    American journal of kidney diseases : the official journal of the National Kidney Foundation·2000
    Same author

    Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

    Controlled clinical trials·1999
    Same author

    Cost effectiveness of carvedilol for heart failure.

    The American journal of cardiology·1999
    Same author

    Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.

    American journal of nephrology·1998
    Same journal

    Preserving the art of nephrology nursing.

    ANNA journal·2000
    Same journal

    Categorizing the response to Epoetin alfa therapy. Case study of the anemic patient.

    ANNA journal·2000
    Same journal

    Improving adequacy of dialysis: using in-series dialyzers.

    ANNA journal·2000
    Same journal

    Putting the pleasure back into eating for the elderly on a maintenance hemodialysis diet!

    ANNA journal·2000
    Same journal

    Does iron cause bacterial infections in patients with end stage renal disease?

    ANNA journal·2000
    Same journal

    Effects of psychosocial education on adaptation in elderly hemodialysis patients.

    ANNA journal·2000
    See all related articles

    Transfusion therapy for anemia in end-stage renal disease (ESRD) is being reassessed due to risks. Recombinant human erythropoietin (epoetin) offers a safer, sustained alternative, improving patient quality of life and altering nursing care.

    Area of Science:

    • Nephrology
    • Hematology
    • Nursing Care

    Background:

    • Anemia is a common complication of end-stage renal disease (ESRD).
    • Traditional treatment for ESRD anemia involved blood transfusions, posing risks like disease transmission and offering only temporary symptom relief.
    • Concerns regarding transfusion safety and efficacy have prompted a re-evaluation of treatment strategies.

    Purpose of the Study:

    • To evaluate recombinant human erythropoietin (epoetin) as an alternative to transfusion therapy for ESRD anemia.
    • To assess the impact of epoetin therapy on patient quality of life.
    • To identify changes in nursing roles associated with epoetin use in ESRD patients.

    Main Methods:

    • Review of current treatment practices for anemia in ESRD.

    Related Experiment Videos

  • Comparison of transfusion therapy with epoetin therapy regarding safety and efficacy.
  • Assessment of patient-reported outcomes and quality of life improvements.
  • Analysis of evolving nursing responsibilities in managing epoetin therapy.

    • Main Results:

    • Epoetin therapy provides sustained reversal of anemia in ESRD patients.
    • Epoetin therapy avoids the risks associated with blood transfusions, such as blood-borne disease transmission.
    • Patients treated with epoetin experience significant improvements in their quality of life.
    • The introduction of epoetin necessitates new approaches to medical management and tailored supportive care by nurses.

    Conclusions:

    • Recombinant human erythropoietin (epoetin) is a superior alternative to transfusion therapy for managing anemia in end-stage renal disease.
    • Epoetin therapy enhances patient quality of life and reduces transfusion-related risks.
    • Nursing care models must adapt to address the unique medical and supportive needs of ESRD patients undergoing epoetin treatment.